Comparing iShares Biotechnology ETF (NASDAQ:IBB) & BlackRock MuniVest Fund II (NYSE:MVT)

iShares Biotechnology ETF (NASDAQ:IBB) and BlackRock MuniVest Fund II (NYSE:MVT) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Dividends

iShares Biotechnology ETF pays an annual dividend of $0.38 per share and has a dividend yield of 0.3%. BlackRock MuniVest Fund II pays an annual dividend of $0.57 per share and has a dividend yield of 5.7%.

Risk & Volatility

iShares Biotechnology ETF has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, BlackRock MuniVest Fund II has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for iShares Biotechnology ETF and BlackRock MuniVest Fund II, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iShares Biotechnology ETF	0	39	108	2	2.70
BlackRock MuniVest Fund II	0	0	0	0	0.00

iShares Biotechnology ETF currently has a consensus price target of $126.96, indicating a potential upside of 0.00%. Given iShares Biotechnology ETF’s stronger consensus rating and higher probable upside, equities research analysts plainly believe iShares Biotechnology ETF is more favorable than BlackRock MuniVest Fund II.

Institutional & Insider Ownership

62.5% of iShares Biotechnology ETF shares are held by institutional investors. Comparatively, 34.2% of BlackRock MuniVest Fund II shares are held by institutional investors. 1.0% of BlackRock MuniVest Fund II shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iShares Biotechnology ETF and BlackRock MuniVest Fund II’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iShares Biotechnology ETF	N/A	N/A	N/A
BlackRock MuniVest Fund II	N/A	N/A	N/A

Earnings & Valuation

This table compares iShares Biotechnology ETF and BlackRock MuniVest Fund II”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A
BlackRock MuniVest Fund II	$4.73 million	45.01	N/A	N/A	N/A

Summary

iShares Biotechnology ETF beats BlackRock MuniVest Fund II on 6 of the 9 factors compared between the two stocks.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

About BlackRock MuniVest Fund II

BlackRock MuniVest Fund II, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in long-term municipal bonds exempt from federal income taxes. BlackRock MuniVest Fund II, Inc. was formed on March 29, 1993 and is domiciled in United States.